BCCA before 12 x 4Gy of 6 MeV

1. L.R. Rosen1, A. Willett1,2, B.W. Fischer-Valuck1,2, S. Katz1, M. Durci1, T. Wu1, 1Willis Knighton Cancer Center, Shreveport, LA, 2 Louisiana State University School of Medicine – Shreveport, Shreveport, LA Introduction Non-melanoma skin cancers (NMSC) are the most common malignancies in the United States. Current treatment options include surgery, topical medications and radiation therapy. HDR brachytherapy has recently emerged as a treatment option, particularly for anatomically challenging locations as well as for patients who require fewer treatments. Methods All patients treated with RT had biopsy proven squamous cell carcinoma (46%) or basal cell carcinoma (54%)with a cohort limited to Stages I or II NMSC in the head, neck or extremities. Acute skin toxicity was evaluated throughout treatment. Local control rates and physician graded cosmetic outcome (poor, fair, good, excellent) were also monitored. *Evans et al IJROBP 1997 Comparison of HDR Brachytherapy, OrthovoltageX-ray, and Electron Beam Radiation in the Treatment of Non-Melanoma Skin Cancers: A Single Institution Experience of Individualized Radiation Therapy Results BCCA Day 9 BCCA before 13 x 4Gy of 100kV BCCA after 13 x 4Gy of 100kV BCCA Day 0 BCCA Day 18 BCCA before 12 x 4Gy of 6 MeV *Good or Excellent based on RTOG Cosmesis Criteria **Grade 3 or 4 in Common Terminology Criteria for Adverse Events Discussion BCCA before 7 x 7Gy of IR192 HDR BCCA after 7 x 7Gy of IR192 HDR Multiple radiation modalities provide excellent local control and cosmetic outcome in patients with NMSC, and acute toxicity is tolerable. Individualized treatment based on anatomical location, cosmetic outcome desired, and patient preference should be considered when utilizing RT in the treatment of NMSC. BCCA 8 Days After BCCA 35 Days After BCCA 84 Days After BCCA after 12 x 4Gy of 6 MeV